Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
A randomized trial of the efficacy and tolerability of the COX-2 inhibitorrofecoxib vs ibuprofen in patients with osteoarthritis
Autore:
Day, R; Morrison, B; Luza, A; Castaneda, O; Strusberg, A; Nahir, M; Helgetveit, KB; Kress, B; Daniels, B; Bolognese, J; Krupa, D; Seidenberg, B; Ehrich, E;
Indirizzi:
St Vincents Hosp, Darlinghurst, NSW 2010, Australia St Vincents Hosp Darlinghurst NSW Australia 2010 rst, NSW 2010, Australia Merck Res Labs, Rahway, NJ USA Merck Res Labs Rahway NJ USAMerck Res Labs, Rahway, NJ USA Clin San Pablo, Surca Lima, Peru Clin San Pablo Surca Lima PeruClin San Pablo, Surca Lima, Peru Clin Angloamer, Lima, Peru Clin Angloamer Lima PeruClin Angloamer, Lima, Peru Rambam Med Ctr, Haifa, Israel Rambam Med Ctr Haifa IsraelRambam Med Ctr, Haifa, Israel Martina Hansens Hosp, Baerum, Norway Martina Hansens Hosp Baerum NorwayMartina Hansens Hosp, Baerum, Norway
Titolo Testata:
ARCHIVES OF INTERNAL MEDICINE
fascicolo: 12, volume: 160, anno: 2000,
pagine: 1781 - 1787
SICI:
0003-9926(20000626)160:12<1781:ARTOTE>2.0.ZU;2-S
Fonte:
ISI
Lingua:
ENG
Soggetto:
NONSTEROIDAL ANTIINFLAMMATORY DRUGS; PROSTAGLANDIN G/H SYNTHASE-1; INDUCIBLE CYCLOOXYGENASE; DIFFERENTIAL INHIBITION; ENDOPEROXIDE SYNTHASE; SELECTIVE-INHIBITION; ENDOTHELIAL-CELLS; MESSENGER-RNA; EXPRESSION; ASPIRIN;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
39
Recensione:
Indirizzi per estratti:
Indirizzo: Morrison, B Merck & Co Inc, 126 E Lincoln Ave,RY 32-641, Rahway, NJ 07065 USA Merck & Co Inc 126 E Lincoln Ave,RY 32-641 Rahway NJ USA 07065
Citazione:
R. Day et al., "A randomized trial of the efficacy and tolerability of the COX-2 inhibitorrofecoxib vs ibuprofen in patients with osteoarthritis", ARCH IN MED, 160(12), 2000, pp. 1781-1787

Abstract

Background: Nonsteroidal anti-inflammatory drugs (NSAIDs) inhibit both cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2). It is not known whethera specific inhibitor of COX-2 will provide efficacy in osteoarthritis (OA)comparable with NSAIDs. Therefore, we compared the efficacy and safety of the rofecoxib, which specifically inhibits COX-2, with those of the NSAID ibuprofen in patients with OA. Objective: To compare the clinical efficacy and tolerability of rofecoxib (12.5 and 25 mg once daily) with ibuprofen (800 mg 3 times daily). Methods: A randomized, double-blind trial of 809 adults with OA was conducted. Patients with OA in whom the knee or hip was the primary source of pain were randomized to 1 of 4 treatment groups on demonstration of disease activity: placebo; rofecoxib, 12.5 or 25 mg once daily; or ibuprofen, 800 mg 3 times daily. Clinical efficacy and safety were monitored during a 6-week treatment period. Results: Both doses of rofecoxib demonstrated efficacy clinically comparable with ibuprofen as assessed by 3 primary end points (pain walking on a flat surface [Western Ontario and McMaster Universities Osteoarthritis Index], patient global assessment of response to therapy, and investigator globalassessment of disease status) according to predefined comparability criteria. Both rofecoxib doses and the ibuprofen dose provided significantly (P<.001) greater efficacy than placebo on all primary end points. Results from secondary end points were consistent with those of the primary end points. All treatments were well tolerated; the overall incidence rates of clinicaladverse experiences were not significantly different (P>.05) among the treatment groups. Conclusion: Rofecoxib was well tolerated and provided clinical efficacy comparable with a high dose of the NSAID ibuprofen.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 07/08/20 alle ore 06:28:05